• Felix Eduardo R Punzalan, Eva Maria C Cutiongco-de la Paz, Jose Jr B Nevado, Jose Donato A Magno, Deborah Ignacia D Ona, Aimee Yvonne Criselle L Aman, Marc Denver A Tiongson, Elmer Jasper B Llanes, Paul Ferdinand M Reganit, Richard Henry P Tiongco, Lourdes Ella G Santos, Jaime Alfonso M Aherrera, Lauro L Abrahan, Charlene F Agustin, Adrian John P Bejarin, and Rody G Sy.
• Department of Internal Medicine, University of the Philippines - Philippine General Hospital, Manila.
• Medicine (Baltimore). 2022 Feb 4; 101 (5): e28703e28703.

AbstractGenetic variation is known to affect response to calcium channel blockers (CCBs) among different populations. This study aimed to determine the genetic variations associated with poor response to this class of antihypertensive drugs among Filipinos.One hundred eighty one hypertensive participants on CCBs therapy were included in an unmatched case-control study. Genomic deoxyribonucleic acid were extracted and genotyped for selected genetic variants. Regression analysis was used to determine the association of genetic and clinical variables with poor response to medication.The variant rs1458038 near fibroblast growth factor 5 gene showed significant association with poor blood pressure-lowering response based on additive effect (CT genotype: adjusted OR 3.41, P = .001; TT genotype: adjusted OR 6.72, P < .001).These findings suggest that blood pressure response to calcium channels blockers among Filipinos with hypertension is associated with gene variant rs1458038 near fibroblast growth factor 5 gene. Further studies are recommended to validate such relationship of the variant to the CCB response.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

24 keywords...

hide…